Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Semaglutide

A modified GLP-1 analogue with approved, formulation-specific medicines and large randomized human trials—evidence that does not establish the identity or suitability of an unrelated catalogue vial.

Aliases reviewed
Semaglutide, GLP-1 receptor agonist (drug class)
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
SubstantialLarge randomized trials of specific formulations in defined populations.
Animal/cell
Not rated
Approved medicine
Approved product existsPrescription medicines in Canada and the U.S., each for a specific formulation and use.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“The molecule has strong evidence. The evidence still belongs to exact medicines, formulations, populations, and indications—not to anything sharing the ingredient name.”

Semaglutide is the outlier in this library: it has extensive human evidence and approved medicines. That makes formulation boundaries more important, not less. An active ingredient's clinical record does not turn a research vial into an approved prefilled pen or tablet.

Identity and established aliases

Semaglutide is a modified analogue of human glucagon-like peptide-1 (GLP-1) and an agonist at the GLP-1 receptor. Its peptide backbone includes changes that resist DPP-4 degradation and a fatty-diacid side chain that promotes albumin binding and prolongs exposure.

Ozempic, Rybelsus, and Wegovy are medicine brand names, not aliases for every semaglutide material. Their excipients, presentations, manufacturing controls, routes, and approved indications differ.

Why researchers study it

GLP-1 receptor signalling affects glucose-dependent insulin secretion, glucagon secretion, gastric emptying, appetite, and energy intake. Large programmes have measured glycemic outcomes, body weight, cardiovascular events, kidney outcomes, liver histology, adverse events, and patient-reported function.

Approved medicines and investigational uses

Health Canada's database lists prescription semaglutide products including subcutaneous Ozempic and Wegovy presentations and oral Rybelsus tablets. A Canadian Notice of Compliance records a cardiovascular-risk indication added for Rybelsus. The database listing itself gives no indication text, and the current product monograph for each medicine—not this summary—defines its Canadian authorization.

In the United States, current FDA labels identify Ozempic injection for glycemic control in adults with type 2 diabetes, cardiovascular-risk reduction in a specified type 2 diabetes population, and kidney/cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. Wegovy injection and tablets have distinct labelled uses; the current injection label includes long-term weight reduction, cardiovascular-risk reduction in a specified population, and accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis in adults.

Investigational work has examined other questions. A small randomized alcohol-use-disorder study measured laboratory alcohol self-administration, drinking patterns, and craving. Large early-Alzheimer's trials measured cognition and daily function and reported no clinical benefit. Neither condition is an FDA- or Health Canada-approved semaglutide indication in the sources reviewed.

What human studies show

STEP 1 randomized 1,961 adults with overweight or obesity and no diabetes to a specific once-weekly subcutaneous semaglutide regimen or placebo alongside lifestyle intervention. At 68 weeks the semaglutide group lost substantially more weight on average; gastrointestinal events and discontinuations were more frequent. The result belongs to that trial population, regimen, comparator, and manufactured study product.

SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. The primary cardiovascular composite occurred less often with semaglutide than placebo, while adverse events leading to permanent discontinuation were more frequent. These findings informed a particular approved cardiovascular indication; they are not evidence for general prevention in people outside the studied population.

What cells and animal studies show

Regulatory labels describe rodent thyroid C-cell tumours at clinically relevant exposures. The human relevance is unknown, which is why the labels carry a boxed warning rather than claiming that the same tumour effect has been established in people. Animal observations help identify hazards; they do not substitute for human outcome data.

Online discussion often compresses semaglutide into a generic promise of weight loss, metabolic repair, or protection from many diseases. The evidence supports exact labelled uses and defined research questions, not universal benefit. Early signals in alcohol-use research remain preliminary, and the large Alzheimer's programme did not show the hoped-for clinical effect.

What remains uncertain

Known label risks include pancreatitis, gallbladder disease, severe gastrointestinal reactions, volume-depletion kidney injury, hypersensitivity, and route- and population-specific cautions; labels also describe the unresolved human relevance of rodent thyroid tumours. Long-term benefit-risk varies by indication and population and continues to be monitored.

Most importantly for this site, clinical evidence for approved pens and tablets does not establish the identity, concentration, purity, sterility, endotoxin status, stability, bioavailability, safety, or effectiveness of a catalogue research material.

NOT SCIENTIFIC EVIDENCE

Anecdotal reports

These are attributed accounts of why someone said they used this compound, from published reporting. A report shows only that someone said something. It does not show that the compound works, that it is safe, how often it is used, or that one thing caused another, and it is not a recommendation. These reports do not count toward the evidence summary above.

  1. Anecdotal report · news report quoting individuals

    Can Ozempic reduce cravings for alcohol and other addictions? Woman shares her story (external link)

    TODAY (by A. Pawlowski) · (The page shows only an updated date.)

    Reported purpose
    A woman profiled in a TODAY report, described as pre-diabetic and as having a doctor who wanted her to lose weight, used Wegovy (semaglutide); the article describes her weight loss as a boost she says she needed to prevent herself from developing type 2 diabetes.
    Compound actually discussed
    Wegovy, a branded approved semaglutide medicine, as named by the article. This is not a research or catalogue material.
    What this source can and cannot establish
    Only that a news report exists in which one person described why she used Wegovy. It does not establish effectiveness, safety, causality, typical use, or anything about catalogue semaglutide.
    What the scientific sources say
    The FDA Wegovy label lists formulation-specific U.S. uses, including long-term weight reduction. Health Canada's Drug Product Database lists Wegovy among marketed Novo Nordisk products; the database does not give indication text, and the current Canadian product monograph defines the authorized uses. STEP 1 measured weight outcomes for one regimen in 1,961 adults with overweight or obesity and without diabetes, and that result belongs to that population, regimen and study product. Type 2 diabetes prevention does not appear among the Wegovy uses summarised in the profile. On alcohol, the profile cites only a small, short, early-phase randomized pilot in 48 adults with alcohol use disorder that measured laboratory self-administration, craving and drinking; those signals are preliminary, and alcohol use disorder is not an approved semaglutide indication in the sources reviewed. None of this transfers to a research material.Sources: FDA prescribing information: Wegovy injection and tablets; Health Canada DPD: Novo Nordisk product search containing semaglutide records; STEP 1: once-weekly semaglutide in adults with overweight or obesity; Randomized semaglutide pilot in alcohol use disorder.
    Uncertainties
    The article does not say explicitly that the medicine was prescribed, only that her doctor wanted her to lose weight. The article's focus is her later self-reported loss of interest in alcohol, which it calls an unexpected side effect and which was not her reason for starting. The article itself says the evidence is "all anecdotal data so far". A researcher it describes as leading a clinical trial on the question said "the extent of the anecdotal data has really outpaced any clinical data"; that trial's later published results are the small pilot cited in the profile. A quoted physician said the effect occurs in some patients and not others and is disclosed as a scientific adviser to the medicine's manufacturer. The article was published while that trial was under way and before its results were published.

    Source accuracy and wording independently reviewed Oct 28, 2026.

What this profile is—and is not

Published with Canadian and U.S. label checks current to the source date; product indications change and require periodic regulatory re-checking.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.